Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 57.5 percent increase over losses of $(0.80) per share from the same period last year. The company reported quarterly sales of $1.494 million which missed the analyst consensus estimate of $5.467 million by 72.67 percent.